⚠️ RESEARCH PURPOSES ONLY — This compound is not FDA authorized for human consumption. All referenced data is presented for informational and educational purposes only.
Ipamorelin 5MG
$40.00
How It Works
The first truly selective GH secretagogue — GH release without cortisol, ACTH, or prolactin elevation
Ghrelin Receptor Activation
Ipamorelin selectively binds Growth Hormone Secretagogue Receptor 1a (GHSR-1a) on anterior pituitary somatotrophs, triggering GH release in a dose-dependent manner. It acts via the same receptor as ghrelin but with greater selectivity and without the appetite-stimulating off-target effects.
- Selective GHSR-1a (ghrelin receptor) agonism
- Dose-dependent GH release (ED50: 80 nmol/kg)
- No desensitization with repeated administration
No Cortisol or Prolactin Elevation
Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate ACTH, cortisol, or prolactin at doses that produce substantial GH release. This was demonstrated in dose-escalation studies and marks ipamorelin as the first pentapeptide GH secretagogue with this selectivity profile.
- No ACTH or cortisol elevation (unlike GHRP-6)
- No significant prolactin elevation
- Clean pituitary selectivity
Physiologic GH Secretion Pattern
Ipamorelin stimulates GH release in discrete, pulsatile bursts similar to endogenous GH secretion physiology. This pulsatile pattern is considered more physiologically appropriate than continuous GH elevation, and is preserved across multiple administration cycles.
- Preserves pulsatile GH secretion pattern
- Peak GH at approximately 40 minutes post-dose
- Additive effect when combined with GHRH analogs
What Research Has Shown
Key findings from preclinical and pharmacological studies — Raun et al. 1998, Frieboes et al. 2004
Research Applications
Primary areas of investigation
Selective GH Secretagogue
First pentapeptide GH secretagogue shown to stimulate GH release without elevating cortisol, ACTH, or prolactin — establishing a new selectivity benchmark for GHS research.
Raun et al. 1998 ↗GH Secretion & Sleep
Human study demonstrated that ipamorelin elevated GH during early nocturnal sleep phases, supporting research into GH secretion during sleep-wake cycles without cortisol disruption.
Frieboes et al. 2004 ↗Bone Growth Models
Dose-dependent bone growth observed in rat models: 52 vs 42 µm/day at effective doses, confirming GH-mediated downstream effects on skeletal tissue in preclinical studies.
Raun et al. 1998 ↗Synergy with GHRH Analogs
Ipamorelin acts via a complementary receptor (GHSR-1a) to GHRH analogs like CJC-1295. Combination protocols are studied to leverage dual-pathway GH stimulation for additive effects on GH pulse amplitude.
Raun et al. 1998 ↗Compound Information
Technical specifications